Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCO-48 Fumarate in Healthy Subjects
NCT04309526Phase 1Completed
- Sponsor
- Nucorion Pharmaceuticals
- Start
- Mar 2020
- Primary completion
- Aug 2020
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatitis B (HBV) comparing NCO-48 Fumarate with Placebo (2 arms). Primary endpoint: Severity of all Adverse Events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) at 30 days. Started Mar 2020; status: completed.
02
Drugs
NUC-1010
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04309526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309526.